Results 41 to 50 of about 9,912 (208)

Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review [PDF]

, 2014
The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers.
A Juutilainen, AA Riedel, AI Adler, AJ Garber, AR Saltiel, BD Green, BI Yan, BM Scirica, Brian C. Y. Fong, C Castell, C Levetan, Carmen K. M. Fan, CC Cowie, CE Van Dijk, CJ Bailey, CN Chan, Daisy D. X. Zhang, DC Simonson, DR Owens, DS Schade, FA Guisasola, François Blachier, Harry H. X. Wang, J Lopatynski, J Mest H, J Rosenstock, K Kaku, Kirin Q. L. Liu, L Groop, M Kobayashi, M Stumvoll, M Takihata, Mandy W. M. Kwan, Martin C. S. Wong, MC Wong, N Inagaki, N Inagaki, O Mosenzon, R Kawamori, RA DeFronzo, S Aronoff, S Clement, SE Kahn, SE Kahn, SE Nissen, Shannon T. S. Li, Sian M. Griffiths, Sky W. M. Chan, SL Zhang, T Kadowaki, V Mohan, W Gareth, W Yang, WB White, Y Guan, Y Seino, Y Seino, YG Kim, Z Zeng   +58 more
core   +3 more sources

The development of type 2 diabetes amongst sibling pairs in the South‐South region of Nigeria: The effect of genetics, environment and lifestyle

Diabetic Medicine, EarlyView.
Abstract Introduction Type 2 diabetes is a complex condition with a multifactorial pathogenesis. The pathogenesis is considered to be polygenic due to complex interactions between genetic/epigenetic and environmental factors. The aim of this study is to determine the genetic, environmental and lifestyle factors associated with the development of type 2
Sunny Chinenye, Ibi Erekosima, Adrian H. Heald, Gesiye Bozimo, Simon G. Anderson, Samuel Seidu, Kariba Akhidue, Adaeze Ugwu, Chioma Unachukwu, Ibitrokoemi Korubo, Kingsley Chukwuemeka Patrick‐Iwuanyanwu, Victoria Gomba, Uwoma Batubo, Victoria Akanatei, Victor Ken‐Uba, Iyeopu Siminialayi, Sokiprim Akoko, Justin Ideozu, Hamilton Opurum   +18 more
wiley   +1 more source

Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man

Frontiers in Endocrinology, 2019
Vildagliptin blocks glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) inactivation of the meal induced increases in GLP-1 and GIP so that elevated GLP-1 and GIP levels are maintained over 24 h.
James E. Foley
doaj   +1 more source

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes [PDF]

Diabetes & Metabolism Journal, 2013
BackgroundThe aims of this study are to investigate the glycemic efficacy and predictive parameters of vildagliptin therapy in Korean subjects with type 2 diabetes.MethodsIn this retrospective study, we retrieved data for subjects who were on twice-daily
Jin-Sun Chang, Juyoung Shin, Hun-Sung Kim, Kyung-Hee Kim, Jeong-Ah Shin, Kun-Ho Yoon, Bong-Yun Cha, Ho-Young Son, Jae-Hyoung Cho   +8 more
doaj   +1 more source

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen, Po‐Chun Wang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

UJI EFEKTIVITAS DAN KEAMANAN KOMBINASI METFORMIN-VILDAGLIPTIN PADA DIABETES MELITUS TIPE 2 DI RSPAL Dr. RAMELAN SURABAYA

JIIS: Jurnal Ilmiah Ibnu Sina, 2023
Metformin sebagai terapi Diabetes Melitus (DM) lini pertama, yang belum mampu mengontrol glukosa darah pada DM tipe 2. Salah satu golongan Dipeptidyl Peptidase IV Inhibitor (DPP4-I), yakni vildagliptin telah masuk dalam Formularium Nasional yang ...
Dwi Octamy Sari, Amelia Lorensia, Abdul Rahem, Lestiono Lestiono   +3 more
doaj   +1 more source

The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. [PDF]

, 2013
The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively ...
Chakraborty, Sandeep, Dandekar, Abhaya M, Dutta, Mouparna, Ghosh, Anindya S, Goñi, Félix M, Oda, Masataka, Rao, Basuthkar J, Rendón-Ramírez, Adela, Venkatramani, Ravindra, Ásgeirsson, Bjarni   +9 more
core  

The Role of Oxidative Stress in Periodontitis

Journal of Periodontal Research, EarlyView.
Oxidative stress is involved in multiple chemical reactions that take place in different intracellular organelles: mitochondria, rough endoplasmic reticulum, peroxisomes, autophagy, and aging, and can be influenced by exogenous factors: nutrition, physical activity, psychological status, environmental conditions, microbiome, and drugs.
Pedro Bullon, Francesca Giampieri, Beatriz Bullon, Maurizio Battino   +3 more
wiley   +1 more source

Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective

Clinical Medicine Insights: Endocrinology and Diabetes
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels in patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple combination therapy.
Sanjay Kalra, Abdul Hamid Zargar, GR Sridhar, Ashok Kumar Das, Jamal Ahmed, Jagdish Chander Mohan, G Vijayakumar, Ajay Kumar, Rakesh Kumar Sahay, Vageesh Ayer, Kaushik Pandit, Ganapathi Bantwal, Arun Srinivas, AG Unnikrishnan, Sushil Jindal, Saumitra Ray, Manash P Baruah, Kajal Ganguly, Sachin Mittal, Ameya Joshi, Joe George, Ganesh HK, Nitin Kapoor, Santosh Ramakrishnan, Chetan Shah, Atul Dhingra, Balram Sharma   +26 more
doaj   +1 more source

Childhood cancer in Iceland 1981-2006 [PDF]

, 2010
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn Skoða/Opna(view/open)BACKGROUND: Childhood cancer is the second most common cause of death in children. The aim of this study was to gather epidemiological information
Guðmundur K. Jónmundsson, Jón Gunnlaugur Jónasson, Jón R. Kristinsson, Trausti Óskarsson, Ásgeir Haraldsson, Ólafur Gísli Jónsson   +5 more
core   +1 more source